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Dox is the most effective chemotherapeutic drug in the clinical treatment of 
cancer. It could cause the severe side effects and induce the multidrug resistance 
easily due to lack of targeting moieties, resulting in the failure of chemotherapy. 
Therefore, the development of novel nanodrug formulation highly integrating actively 
targeted delivery, multimodal combination therapy, and integration of diagnosis and 
therapy has become an important research direction in the modern tumor therapy. 
Multimodal imaging-guided multistage targeted synergistic combination therapy 
possesses many advantages including increased tumoricidal effect, reduced toxicity, 
and retarded drug resistance. Herein, we have elaborately developed a 
core-interlayer-shell structure Fe3O4@mSiO2@lipid-PEG-methotrexate nanoparticle 
(FMLM) to realize photodynamic-chemical combination therapy under the guidance 
of magnetic resonance-fluorescence imaging. 
The study was designed that the Fe3O4 core was used for 
magnet-stimulate-response drug release, magnetic resonance imaging (MRI), and 
early-phase magnet targeting ability; the mSiO2 layer could encapsulate anticancer 
drug Doxorubicin (Dox) for chemotherapy; and the protective shell of lipid-PEG and 
lipid-PEG-methotrexate offered later-phase specific cellular targeting ability, good 
water dispersibility, and loading of photosensitizer zinc phthalocyanine (ZnPc) for 
simultaneous near-infrared fluorescence imaging and photodynamic therapy. Based on 
the above design research, the paper mainly discusses the content of the following 
aspects： 
In construction of drug-loading nanoparticles, we surveyed the preparation 
methods of Fe3O4, FM, FML, and FMLM nanoparticles, respectively. To guarantee 
the controllable synthesis method, the single factor and orthogonal experiment design 
were conducted to optimize experiment conditions. Particle size, potential, TEM, 
SEM, EDS, XRD, N2 adsorption desorption, IR spectra, time of flight mass 
spectrometry and hysteresis curve etc were used to characterize the Fe3O4, FM, FML, 
and FMLM nanoparticles. These results demonstrated that the prepared FMLM 
nanoparticles had a clear core-interlayer-shell structure, the structure was intact, and 
nearly spherical. The both Dox and ZnPc-loaded FMLM nanoparticles 
















of -22.60 mV. The drug encapsulation efficacy of ZnPc was 98.80%, drug-loading 
content of Dox was 0.4959 mg/mg. So the FMLM nanoparticles have the potential to 
be a good nanoscaled drug carrier. 
To study the application of FMLM nanoparticles drug delivery system in 
photodynamic-chemical combination therapy under the guidance of magnetic 
resonance-fluorescence imaging, we conducted a systematic evaluation of in vivo and 
in vitro. 
Experiments had studied the in vitro release curve of Dox-FM and Dox-FMLM, 
and explore its mechanism of drug release. Meanwhile, under the additional 
alternating magnetic field (AMF), drug release was increased, indicating the drug 
release behavior has the characteristics of pH-sensitivity and magnetic responsiveness. 
We further explored the ability of singlet oxygen generation of drug-loading 
nanoparticles, the result proved that the ZnPc-nanoparticles have the feasibility of 
photodynamic therapy; Furthermore, we have carried on the evaluation system of the 
cells, such as cytotoxicity, cellular uptake, Cell apoptosis,etc. These results confirmed 
the difference of FMLM nanoparticles caused by MTX cell active targeting cell in 
cytotoxicity and cellular uptake. Besides, the preliminary mechanism of apoptosis of 
HeLa was explored. 
In vivo evaluation of drug-loading nanoparticles were conducted,such as in vivo 
pharmacokinetic, living fluorescence test, animal toxicity test and tumor inhibition 
experiment, confirming the superiority of the magnetic targeting and cell active 
targeting multistage targeted, the safety of drug-loading nanoparticles and the 
feasibility of chemotherapy-photodynamic collaboration for the treatment of tumor. In 
vivo experiment, we verified the potential of Dox/ZnPc-FMLM in multimodal 
imaging. Integrate fluorescence imaging (FI), MRI and photoacoustic imaging (PAI) 
into Dox/ZnPc-FMLM nanoparticles can make up the shortcomings of individual 
imaging, foster strengths and circumvent weaknesses, to achieve accurate diagnosis 
and treatment. These results indicated magnet targeting cooperative with methotrexate 
macromolecular prodrug targeting is successfully exploited to develop a promising 
versatile theranostic nanoplatform for dual-modal fluorescence and magnetic 
resonance imaging-guided combined chemo-photodynamic cancer therapy. 




















AMF    Alternating magnetic field 
ABDA    9,10-anthracenediyl-bis(methylene) dimalonic acid 
CTAB    Cetyl trimethyl ammonium bromide  
Dox    Doxorubicin 
Dox-FMLM  Dox-loaded FMLM 
Dox-FM   Dox-loaded FM 
Dox/ZnPc-FMLM Dox and ZnPc-loaded FMLM 
Dox/ZnPc-FML  Dox and ZnPc-loaded FML 
DMSO    Dimethylsulfoxide 
DCC    Dicyclohexylcarbodiimide 
DPPC    1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
EPR    Enhanced permeation retentioneffect 
EF     Encapsulation efficiency  
FM     Fe3O4@mSiO2 
FML    Fe3O4@mSiO2@lipid-PEG 
FMLM    Fe3O4@mSiO2@lipid-PEG-methotrexate 
FI     Fluorescence imaging 
FTIR    Fourier transform infrared spectroscopy 
HEPES    4-(2-hydroxyethyl)-1-pipera-zineethanesulfonic acid 
MTX    Methotrexate 
MRI    Magnetic resonance imaging 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MPS    Mononuclear phagocyte system 
NHS    N-hydroxysuccinimide 
PDT    Photodynamics therapy 
PDI    Polydispersity index 
PBS    Phosphate buffer saline 
PAI     Photoacoustic imaging 
ROS    Reactive oxygen species 
RES    Reticuloendothelial system 
RBCs    Red blood cells 
SEM-EDS   Scanning electron microscope-energydispersive analysis 
TEM    Transmission electron microscope 
TEA    Triethylamine 
UV-vis    Ultraviolet-visible spectroscopy 
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30 年的历史[3]。它的主要磁性来源是 Fe3O4以及 γ-Fe2O3，且其制备方法多种多
样，如微乳液法[4]、溶胶凝胶法[5]、水热法[6]、高温分解法[7]等。作为应用广泛































图 1.1 磁性纳米粒为基础的肿瘤诊疗策略 

























Degree papers are in the “Xiamen University Electronic Theses and Dissertations Database”. Full
texts are available in the following ways: 
1. If your library is a CALIS member libraries, please log on http://etd.calis.edu.cn/ and submit
requests online, or consult the interlibrary loan department in your library. 
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn for delivery details.
厦
门
大
学
博
硕
士
论
文
摘
要
库
